Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles 2022: Biology, Disease & Medicine

Chi-Ju Kim's Biography

Chi-Ju Kim, Postdoctoral Research Fellow, Johns Hopkins University School of Medicine

Dr. Chi-Ju Kim is a postdoctoral research fellow in the Kenneth Pienta-Sarah Amend laboratory at Johns Hopkins University School of Medicine. He comes to the field of cancer biology accompanied by many biomedical engineering skills gained in the development of a microfluidic device for liquid biopsy applications (extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor cells (CTCs), and platelets). He is committed to pursuing a career in academic research to develop microfluidic systems for translational biomedical sciences, especially in understanding and discovering the critical mechanism leading to lethal cancer. The ultimate career goal is to cure cancer and to improve cancer patients’ lives through the realization of personalized precision medicine. He has already made major contributions to the improvement of disease treatment management, particularly for cancer, including: (i) developing fully automated isolation methods of cfDNA, EVs, and platelets from whole blood, (ii) developing fully automated platelet function tests. Currently, his research involves investigating the implication of nucleus morphology in the polyaneuploid cancer cell (PACC) state on therapeutic recurrence and on developing novel microfluidic systems to define the critical role of EVs in tumor microenvironments and how they contribute to tumorigenesis. The combination of his Ph.D. research in biomedical engineering with the training in cancer biology gained during his postdoctoral fellowship uniquely suits him to build his own research field, stipulated as translational biomedical research, by both proposing a novel model of cancer biology and developing a realizable microfluidic system to elucidate mechanisms of metastasis and therapeutic resistance.

Chi-Ju Kim Image

The Polyaneuploid Cancer Cell (PACC) State Promotes Therapeutic Resistance Through Extracellular Vesicles (EVs)

Wednesday, 14 September 2022 at 17:00

Add to Calendar ▼2022-09-14 17:00:002022-09-14 18:00:00Europe/LondonThe Polyaneuploid Cancer Cell (PACC) State Promotes Therapeutic Resistance Through Extracellular Vesicles (EVs)Extracellular Vesicles 2022: Biology, Disease and Medicine in

The Johns Hopkins Cancer Ecology Center recently discovered a novel form of cancer therapeutic resistance achieved through the polyaneuploid cancer cell (PACC) state. The PACC state is triggered through a conserved evolutionary program that results in sustained polyploidization of the aneuploid genome. Cells in the PACC state are resistant to all therapies, not only the stressor that induced entry into the PACC state, and that the cell population that arises from the induced PACC state likewise shows reduced sensitivity to multiple agents. Clinically, the presence of cells in the PACC state in radical prostatectomy specimens of prostate cancer (PCa) patients increases the risk of progression. Utilizing a novel extracellular vesicle (EV) isolation platform, combined with development of a 3D imaging-based cellular EV uptake assay as well as a multiplexed EV RNA cargo profiling method, it was discovered that PACCs release significantly larger numbers of EVs. It is hypothesized that EVs contain factors (i.e., multidrug resistance proteins) that transmit resistance to adjacent cancer cells. An understanding of PACC-derived EVs and the impact of the transferred EV cargo on the phenotype of therapeutic-sensitive cells will provide critical insight into the acquisition of therapy resistance in lethal cancer.

Add to Calendar ▼2022-09-13 00:00:002022-09-14 00:00:00Europe/LondonExtracellular Vesicles 2022: Biology, Disease and MedicineExtracellular Vesicles 2022: Biology, Disease and Medicine in